MARKET

OLMA

OLMA

Olema Pharmaceuticals, Inc.
NASDAQ
27.21
-0.43
-1.56%
After Hours: 27.27 +0.06 +0.22% 19:47 12/05 EST
OPEN
27.86
PREV CLOSE
27.64
HIGH
28.25
LOW
25.94
VOLUME
2.16M
TURNOVER
--
52 WEEK HIGH
29.51
52 WEEK LOW
2.860
MARKET CAP
2.14B
P/E (TTM)
-15.0715
1D
5D
1M
3M
1Y
5Y
1D
Olema Pharmaceuticals Grants Stock Options to New Employees Under Inducement Plan
Reuters · 4d ago
OLEMA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 4d ago
Weekly Report: what happened at OLMA last week (1124-1128)?
Weekly Report · 5d ago
Olema Pharmaceuticals (OLMA): Assessing Valuation Following $190 Million Equity Offering and Underwriter Changes
Simply Wall St · 11/28 11:31
Olema Pharmaceuticals (OLMA) Bolsters Balance Sheet but Will Fresh Capital Accelerate Oncology Innovation?
Simply Wall St · 11/26 22:27
Weekly Report: what happened at OLMA last week (1117-1121)?
Weekly Report · 11/24 09:18
LifeSci Capital Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)
TipRanks · 11/22 15:35
Olema Pharmaceuticals to Join Evercore Healthcare Conference
Reuters · 11/21 21:30
More
About OLMA
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.

Webull offers Olema Pharmaceuticals Inc stock information, including NASDAQ: OLMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OLMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OLMA stock methods without spending real money on the virtual paper trading platform.